Transient Pulmonary Infiltrations in Cystic Fibrosis due to Allergic Aspergillosis

Mearns, Margaret B.; Young, W. F.; Batten, John

doi:10.1136/thx.20.5.385

Cited by 76 publications

(24 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…ABPA in CF patients was first described in the 1960s (391,392) and subsequently has been recognized as relatively common, with reported prevalences of 2% to 11% (209,338,381,411,418,419,549,551). The prevalence of ABPA increases with age (209), and it is more common in individuals over 6 years of age (381).…”

Section: Aspergillus Speciesmentioning

confidence: 99%

Clinical Significance of Microbial Infection and Adaptation in Cystic Fibrosis

et al. 2011

View full text Add to dashboard Cite

SUMMARY A select group of microorganisms inhabit the airways of individuals with cystic fibrosis. Once established within the pulmonary environment in these patients, many of these microbes adapt by altering aspects of their structure and physiology. Some of these microbes and adaptations are associated with more rapid deterioration in lung function and overall clinical status, whereas others appear to have little effect. Here we review current evidence supporting or refuting a role for the different microbes and their adaptations in contributing to poor clinical outcomes in cystic fibrosis.

show abstract

Section: Aspergillus Speciesmentioning

confidence: 99%

Clinical Significance of Microbial Infection and Adaptation in Cystic Fibrosis

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Transient pulmonary infiltrates in certain CF patients were first attributed to infection with Aspergillus fumigatus by Mearns et al [147] in 1965. Since that time other investi gators have attempted to determine the role that fungal and bacterial hypersensitivity plays in the progressive pulmonary disease in CF.…”

Section: Allergymentioning

confidence: 99%

Host Defenses in Patients with Cystic Fibrosis: Modulation by <i>Pseudomonas aeruginos</i><i>a</i>

Speert¹

1985

Pathol Immunopathol Res

View full text Add to dashboard Cite

“…Allergic bronchopulmonary aspergillosis (ABPA) is an occasional complication in patients with cystic fibrosis (CF) (1,2,3). Aspergillus Jkmigatus rarely plays a truly invasive role (4).…”

mentioning

confidence: 99%

Serum antibodies toAspergillus fumigatus catalase in patients with cystic fibrosis

Schønheyder

Jensen

Læssøe

et al. 1988

Eur. J. Clin. Microbiol. Infect. Dis.

View full text Add to dashboard Cite

Seven to ten percent of patients with cystic fibrosis had serum antibodies to the catalase antigen of Aspergillus fumigatus in three cross-sectional surveys between 1977 and 1984. A total of 208 patients participated at least once, and the cumulated frequency of catalase antibodies in 94 patients included in all three surveys was 16%. The titre range was 1 to 16. The prevalence rate of Aspergillus fumigatus in sputum was 50% for a 2.5-year observation period. Catalase antibodies were strongly associated with the occurrence of Aspergillus fumigatus in sputum (p = 0.003), and the microorganism was more numerous in colonized patients with catalase antibodies than in those without such antibodies (p = 0.004). Patients with Aspergillus fumigatus in sputum and a positive catalase antibody test tended to have an adverse development as regards lung function compared to both carriers without antibodies and non-carriers. The observed differences could not, however, be related to different rates of chronic Pseudomonas aeruginosa infection.

show abstract

Transient Pulmonary Infiltrations in Cystic Fibrosis due to Allergic Aspergillosis

Cited by 76 publications

References 1 publication

Clinical Significance of Microbial Infection and Adaptation in Cystic Fibrosis

Clinical Significance of Microbial Infection and Adaptation in Cystic Fibrosis

Host Defenses in Patients with Cystic Fibrosis: Modulation by <i>Pseudomonas aeruginos</i><i>a</i>

Serum antibodies toAspergillus fumigatus catalase in patients with cystic fibrosis

Contact Info

Product

Resources

About